Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pharmacopsychiatry. 2012 Mar;45(2):41-6. doi: 10.1055/s-0031-1291217. Epub 2011 Nov 15.

Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial.

Author information

  • 1Geriatric Psychiatry Centre, Maria-Hilf Hospital Krefeld, Krefeld, Germany. ralf.ihl@alexianer-krefeld.de

Abstract

INTRODUCTION:

A 24-week randomised controlled trial was conducted to assess the efficacy of a 240 mg once-daily preparation of Ginkgo biloba extract EGb 761® in 404 outpatients ≥ 50 years diagnosed with mild to moderate dementia (SKT 9-23), Alzheimer's disease (AD) or vascular dementia (VaD), with neuropsychiatric features (NPI total score ≥ 5).

METHODS:

Separate analyses were performed for diagnostic subgroups (probable or possible AD; VaD).

RESULTS:

333 patients were diagnosed with AD and 71 with VaD. EGb 761® treatment was superior to placebo with respect to the SKT total score (drug-placebo differences: 1.7 for AD, p<0.001, and 1.4 for VaD, p<0.05) and the NPI total score (drug-placebo differences: 3.1 for AD, p<0.001 and 3.2 for VaD, p<0.05). Significant drug-placebo differences were found for most secondary outcome variables with no major differences between AD and VaD subgroups. Rates of adverse events in EGb 761® and placebo groups were essentially similar.

CONCLUSION:

EGb 761® improved cognitive functioning, neuropsychiatric symptoms and functional abilities in both types of dementia.

© Georg Thieme Verlag KG Stuttgart · New York.

PMID:
22086747
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Georg Thieme Verlag Stuttgart, New York
    Loading ...
    Write to the Help Desk